We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Analyst Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report) and keeping the price target ...

Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Compared to the aggregate P/E ratio of the 37.23 in the Pharmaceuticals industry, Merck & Co Inc. has a lower P/E ratio of 19 ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by Magnus Ofstad. In this ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that David Arkowitz, M.B.A., has joined the company as Chief Financial Officer.